PF-07321332 Supply Agreement for Pandemic Purposes
Vaccines have been shown to be highly effective in the fight against COVID-19, to date. However, there is a cohort of individuals who either cannot take the vaccine or for whom it is ineffective. There is therefore an urgent need to find an effective alternative. So far there are no primary care antiviral drugs that can be easily dispensed specifically to treat SARS-CoV-2 and prevent its transmission in the community. This agreement is for the procurement of 250,000 units of PF-07321332/ritonavir . It is one of the...
Buyer
Department of Health and Social Care
Value
£2
Published
18 Nov 2021
Closes
17 Oct 2021
Procurement details
Source
Contracts Finder
Region
United Kingdom
Procurement method
Limited
Category
Goods
Contract starts
17 Oct 2021
Contract ends
31 Dec 2022
CPV classifications
33600000
Pharmaceutical products
Lots
Lot default PF-07321332 Supply Agreement for Pandemic Purposes
£1
Vaccines have been shown to be highly effective in the fight against COVID-19, to date. However, there is a cohort of individuals who either cannot take the vaccine or for whom it is ineffective. There is therefore an urgent need to find an effective alternative. So far there are no primary care antiviral drugs that can be easily dispensed specifically to tr...
Delivery: United Kingdom
Documents
Unlock document linkAwarded contract notice on Contracts Finder
17 Nov 2021
Awarded contract notice on Contracts Finder
Award notice · Web page
Annex D1
Not provided
Annex D1
Document
FINAL Project Tyne - Antiviral Supply Agreement Redacted Version 171121_Redacted
Not provided
FINAL Project Tyne - Antiviral Supply Agreement Redacted Version 171121_Redacted
Document
Awarded contract notice on Contracts Finder
18 Nov 2021
Awarded contract notice on Contracts Finder
Award notice · Web page
FINAL - Antiviral Supply Agreement Redacted Version 171121_Redacted
Not provided
FINAL - Antiviral Supply Agreement Redacted Version 171121_Redacted
Document
Contains public sector information licensed under the Open Government Licence v3.0.